Why did Novartis del-desiran phase 3 Harbor trial miss matter?

Novartis’ del-desiran missed the primary endpoint in the phase 3 Harbor trial, creating a setback for what was described as the centerpiece of its $12 billion Avidity Biosciences takeover. The miss raises doubts about the deal’s strategic rationale and could increase scrutiny of Novartis’ pipeline credibility and late-stage RNA-focused acquisitions.